Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 22c; Offers FY23 Revenue Guidance

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.70), $0.22 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $50.14 million versus the consensus estimate of $44.24 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2023 revenue of $180 million, versus the consensus of $174.5 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance